Home News

2017 first half results presentation

Operating revenues, growth data, profitability and the behavior of our products.

Wed, 26/07/2017 - 12:28 0 min
Download related document
No votes yet
 
Related
ROVI announces the acquisition of an injectable drug product manufacturing site...
Laboratorios Farmacéuticos Rovi, S.A. announces that ROIS Phoenix Inc. (the “Buyer”), a wholly owned subsidiary of ROVI Pharma Industrial...
1 min
29/09/2025
First half 2025 results press release
​Operating revenue in the first half of 2025 was 314.6 million euros, a 4% decrease on the first half of 2024, mainly due to the...
3 min
24/07/2025
Final Decision to award aid of 36.3 million euros for ROVI’s LAISOLID project...
  Madrid, 10 July 2025. Laboratorios Farmacéuticos ROVI, S.A. (“ROVI”) announces that, on 9 July 2025, the Technological...
4 min
10/07/2025